{"id":"https://openalex.org/W4405839648","doi":"https://doi.org/10.1016/j.molmed.2024.12.009","title":"Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer","display_name":"Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer","publication_year":2024,"publication_date":"2024-12-27","ids":{"openalex":"https://openalex.org/W4405839648","doi":"https://doi.org/10.1016/j.molmed.2024.12.009","pmid":"https://pubmed.ncbi.nlm.nih.gov/39732571","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13122099"},"language":"en","primary_location":{"id":"doi:10.1016/j.molmed.2024.12.009","doi":"https://doi.org/10.1016/j.molmed.2024.12.009","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.molmed.2024.12.009","pdf_url":null,"source":{"id":"https://openalex.org/S64855341","display_name":"Trends in Molecular Medicine","issn_l":"1471-4914","issn":["1471-4914","1471-499X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-2","ki-jl-1","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in Molecular Medicine","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122099/","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017521822","display_name":"Leire Arrizabalaga","orcid":"https://orcid.org/0000-0003-0423-8350","observed_orcids":["https://orcid.org/0000-0003-0423-8350"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4210112085","display_name":"Navarre Institute of Health Research","ror":"https://ror.org/023d5h353","country_code":"ES","type":"education","lineage":["https://openalex.org/I4210112085"]},{"id":"https://openalex.org/I4392738196","display_name":"Centro de Investigaci\u00f3n M\u00e9dica Aplicada","ror":"https://ror.org/01qew8q20","country_code":"ES","type":"nonprofit","lineage":["https://openalex.org/I4392738196","https://openalex.org/I88155538"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Leire Arrizabalaga","raw_affiliation_strings":["Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IDISNA), Pamplona, Spain","institution_ids":["https://openalex.org/I1289437631","https://openalex.org/I4210112085","https://openalex.org/I4392738196"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019789747","display_name":"Esmeralda Garcia Torralba","orcid":"https://orcid.org/0000-0002-3744-2182","observed_orcids":["https://orcid.org/0000-0002-3744-2182"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]},{"id":"https://openalex.org/I4210091031","display_name":"Hospital General Universitario Morales Meseguer","ror":"https://ror.org/00cfm3y81","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210091031"]},{"id":"https://openalex.org/I4210146619","display_name":"Instituto Murciano de Investigaci\u00f3n Biosanitaria","ror":"https://ror.org/053j10c72","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210146619"]},{"id":"https://openalex.org/I80180929","display_name":"Universidad de Murcia","ror":"https://ror.org/03p3aeb86","country_code":"ES","type":"education","lineage":["https://openalex.org/I80180929"]}],"countries":["ES","US"],"is_corresponding":false,"raw_author_name":"Esmeralda Garc\u00eda-Torralba","raw_affiliation_strings":["Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain; Department of Medicine, Medical School, University of Murcia, Murcia, Spain; IMIB-Arrixaca, Murcia, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain; Department of Medicine, Medical School, University of Murcia, Murcia, Spain; IMIB-Arrixaca, Murcia, Spain","institution_ids":["https://openalex.org/I1289437631","https://openalex.org/I4210091031","https://openalex.org/I4210146619","https://openalex.org/I80180929"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071827163","display_name":"Lorenzo Galluzzi","orcid":"https://orcid.org/0000-0003-2257-8500","observed_orcids":["https://orcid.org/0000-0003-2257-8500"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lorenzo Galluzzi","raw_affiliation_strings":["Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: deadoc80@gmail.com"],"raw_orcid":"https://orcid.org/0000-0003-2257-8500","affiliations":[{"raw_affiliation_string":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: deadoc80@gmail.com","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001622789","display_name":"Aitziber Buqu\u00e9","orcid":"https://orcid.org/0000-0002-7698-8778","observed_orcids":["https://orcid.org/0000-0002-7698-8778"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Aitziber Buqu\u00e9","raw_affiliation_strings":["Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: abuquemartinez@gmail.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: abuquemartinez@gmail.com","institution_ids":["https://openalex.org/I1289437631"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5001622789","https://openalex.org/A5071827163"],"corresponding_institution_ids":["https://openalex.org/I1289437631"],"apc_list":{"value":7030,"currency":"USD","value_usd":7030},"apc_paid":null,"fwci":0.3658,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.63440011,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":95},"biblio":{"volume":"31","issue":"6","first_page":"495","last_page":"497"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cdk2","display_name":"CDK2","score":0.9139999747276306},{"id":"https://openalex.org/keywords/hormone-receptor-positive-breast-cancer","display_name":"hormone receptor-positive breast cancer","score":0.871999979019165},{"id":"https://openalex.org/keywords/cdk4-6-inhibitor-resistance","display_name":"CDK4/6 inhibitor resistance","score":0.9169999957084656},{"id":"https://openalex.org/keywords/cellular-senescence","display_name":"cellular senescence","score":0.8889999985694885},{"id":"https://openalex.org/keywords/senolytics","display_name":"senolytics","score":0.5400000214576721},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6282510757446289},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5491141080856323},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5430348515510559},{"id":"https://openalex.org/C82495950","wikidata":"https://www.wikidata.org/wiki/Q14911732","display_name":"Cyclin-dependent kinase 2","level":4,"score":0.4897732734680176},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4463229179382324},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4362509548664093},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3966892957687378},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.08415189385414124}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016159","descriptor_name":"Tumor Suppressor Protein p53","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016159","descriptor_name":"Tumor Suppressor Protein p53","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016922","descriptor_name":"Cellular Senescence","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051357","descriptor_name":"Cyclin-Dependent Kinase 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051357","descriptor_name":"Cyclin-Dependent Kinase 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.molmed.2024.12.009","doi":"https://doi.org/10.1016/j.molmed.2024.12.009","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.molmed.2024.12.009","pdf_url":null,"source":{"id":"https://openalex.org/S64855341","display_name":"Trends in Molecular Medicine","issn_l":"1471-4914","issn":["1471-4914","1471-499X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-2","ki-jl-1","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in Molecular Medicine","raw_type":"journal-article"},{"id":"pmid:39732571","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39732571","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in molecular medicine","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13122099","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122099/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends Mol Med","raw_type":"Text"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:13122099","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13122099/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends Mol Med","raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000907107","display_name":"Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancer","funder_award_id":"R01CA271915","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320306078","display_name":"U.S. Department of Defense","ror":"https://ror.org/0447fe631"},{"id":"https://openalex.org/F4320308295","display_name":"Leukemia and Lymphoma Society","ror":"https://ror.org/04m0xav37"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320332523","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073"},{"id":"https://openalex.org/F4320332898","display_name":"Stand Up To Cancer","ror":"https://ror.org/01dmpb598"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"},{"id":"https://openalex.org/F6183268228","display_name":"Medisch Centrum Leeuwarden","ror":"https://ror.org/0283nw634"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W2967855006","https://openalex.org/W3024684302","https://openalex.org/W3198894769","https://openalex.org/W4213127856","https://openalex.org/W4220829656","https://openalex.org/W4297183614","https://openalex.org/W4389299182","https://openalex.org/W4389558851","https://openalex.org/W4403299725","https://openalex.org/W4403300758"],"related_works":["https://openalex.org/W7170902509","https://openalex.org/W7167090281","https://openalex.org/W3106785508","https://openalex.org/W4404403319","https://openalex.org/W2299045691","https://openalex.org/W4409633962","https://openalex.org/W3083198770","https://openalex.org/W7129663992","https://openalex.org/W4230445265","https://openalex.org/W4293554483"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-12-27T00:00:00"}